Bardoxolone: Augmenting the Yin in chronic kidney disease

Research output: Contribution to journalReview ArticleOtherpeer-review

1 Citation (Scopus)


Nrf-2 (NF-E2-related factor 2) is a regulator of anti-oxidant, anti-inflammatory and detoxification pathways. Coordinated augmentation of these key defence pathways via Nrf-2 signalling is being investigated for the treatment of chronic diseases, including diabetes and its complications. The first to reach commercial development is the triterpenoid, bardoxolone methyl. In recent clinical trial, bardoxolone rapidly improved kidney function on average by 5-10 ml/min within 4 weeks of therapy. Importantly, this improvement was sustained during one year of active treatment. This suggests that rather that overworking a failing system, bardoxolone appeared to safely augment renal function, at least to one year. If similar improvements in kidney function can be reproduced in the upcoming BEACON trial, it will represent a major advance on conventional therapy and new way to bring balance to the failing kidney.

Original languageEnglish
Pages (from-to)303-304
Number of pages2
JournalDiabetes and Vascular Disease Research
Issue number4
Publication statusPublished - 1 Oct 2011
Externally publishedYes


  • Bardoxolone
  • kidney disease
  • Yin and Yang

Cite this